PRME
$3.71
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States.
Recent News
Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway
Prime Medicine Inc. (NASDAQ:PRME) is one of the best new penny stocks to buy. On March 3, Prime Medicine reported its full-year 2025 financial results, highlighting a shift toward its in vivo liver franchise. The company ended the year with $191.4 million in cash, cash equivalents, and investments, providing a financial runway into 2027. Despite […]
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of +13.39% and -63.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Jacob Funds Bets on Prime Medicine (PRME), a Next-Generation Gene Therapy Company
Jacob Funds, a mutual fund company, released its fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. After an optimistic quarter, equity markets corrected slightly in November. Although overall economic growth has been robust throughout the year, recent divergent data on consumer spending and the labor market have put doubt on future […]
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of +78.85% and -2.78%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Favourable Signals For Prime Medicine: Numerous Insiders Acquired Stock
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...